Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Strata PATH (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid Tumors

Next Previous
X
Search
Trial Profile

Strata PATH (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Enfortumab vedotin (Primary) ; Lorlatinib (Primary) ; Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary) ; Talazoparib (Primary) ; Trastuzumab-deruxtecan (Primary)
  • Indications Solid tumours
  • Focus Biomarker; Therapeutic Use
  • Acronyms StrataPATH
  • Sponsors Strata Oncology

    • Most Recent Events

    • 20 May 2024 Status changed from recruiting to active, no longer recruiting.
    • 07 May 2024 According to a Gilead Sciences media release, data from this trial to be presented in abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 06 Sep 2023 Investigation drug pembrolizumab added to study protocol.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top